Abnormalities, Drug-Induced
"Abnormalities, Drug-Induced" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Descriptor ID |
D000014
|
| MeSH Number(s) |
C16.131.042
|
| Concept/Terms |
Abnormalities, Drug-Induced- Abnormalities, Drug-Induced
- Abnormalities, Drug Induced
- Drug-Induced Abnormalities
- Abnormality, Drug-Induced
- Drug Induced Abnormalities
- Drug-Induced Abnormality
|
Below are MeSH descriptors whose meaning is more general than "Abnormalities, Drug-Induced".
Below are MeSH descriptors whose meaning is more specific than "Abnormalities, Drug-Induced".
This graph shows the total number of publications written about "Abnormalities, Drug-Induced" by people in this website by year, and whether "Abnormalities, Drug-Induced" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Abnormalities, Drug-Induced" by people in Profiles.
-
Kaplan S, Braverman DL, Frishman I, Bartov N. Pregnancy and Fetal Outcomes Following Exposure to Modafinil and Armodafinil During Pregnancy. JAMA Intern Med. 2021 02 01; 181(2):275-277.
-
Giovannoni G, Galazka A, Schick R, Leist T, Comi G, Montalban X, Damian D, Dangond F, Cook S. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety. Drug Saf. 2020 07; 43(7):635-643.
-
Gagne JJ, Maio V, Berghella V, Louis DZ, Gonnella JS. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol. 2008 Nov; 64(11):1125-32.
-
Pollack PS, Shields KE, Burnett DM, Osborne MJ, Cunningham ML, Stepanavage ME. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res A Clin Mol Teratol. 2005 Nov; 73(11):888-96.
-
Shields KE, Wiholm BE, Hostelley LS, Striano LF, Arena SR, Sharrar RG. Monitoring outcomes of pregnancy following drug exposure: a company-based pregnancy registry program. Drug Saf. 2004; 27(6):353-67.
-
Wubah JA, Ibrahim MM, Gao X, Nguyen D, Pisano MM, Knudsen TB. Teratogen-induced eye defects mediated by p53-dependent apoptosis. Curr Biol. 1996 Jan 01; 6(1):60-9.
-
Hurtt ME, Valentine R, Alvarez L. Developmental toxicity of inhaled trans-1,2-dichloroethylene in the rat. Fundam Appl Toxicol. 1993 Feb; 20(2):225-30.